Netherlands· NL-c586f0112240
MYNZEPLI 40 mg/ml oplossing voor injectie in een voorgevulde spuit
A aflibercept product containing aflibercept, registered in Netherlands by Advanz Pharma Limited. The same ATC class is registered in 11 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Aflibercept is registered in 11 of 19 countries.
Countries holding a registration under ATC S01LA05 (aflibercept), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 7 of them publish a price we can compare per daily dose
Aflibercept · ATC S01LA05
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- AFLIBERCEPT
- Manufacturer
- Advanz Pharma Limited
- Country
- Netherlands (NL)
- ATC code
- S01LA05
- ATC class
- Aflibercept
- Defined daily dose
- 0.018 DE, IVT
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/25/1964
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Aflibercept in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaAFIVEGSTADA Arzneimittel AG, Bad Vilbel
- BelgiumAfiveg 40 mg/mlStada Arzneimittel
- SwedenAfiveg 40 mg/ml Injektionsvätska, lösningSTADA Arzneimittel AG
- IcelandAfivegSTADA Arzneimittel AG
- PolandAfivegSTADA Arzneimittel AG
- SpainAFQLIR 40 MG/ML SOLUCION INYECTABLE EN JERINGA PRECARGADASandoz Gmbh
- IrelandAfiveg 40 mg/mL solution for injectionStada Arzneimittel AG
- SwitzerlandAflivis 40 mg/ml, InjektionslösungOmniVision AG
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Vgenfli
- Iceland · Afiveg, Afqlir
- Liechtenstein · Afiveg, Afqlir
- Norway · Afiveg, Afqlir
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fb597e42-22e8-4fc8-8423-27029df6b6f0 GET /v1/drugs/fb597e42-22e8-4fc8-8423-27029df6b6f0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor injectie",
"route": "Intravitreaal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/mynzepli-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Aflibercept",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp133934",
"excipients": [
"HISTIDINE, (L-)",
"HISTIDINEMONOHYDROCHLORIDE 1-WATER (L-)",
"POLOXAMEER 188",
"TREHALOSE (Alpha, Alpha-) 2-WATER",
"WATER VOOR INJECTIE"
],
"substances": [
"AFLIBERCEPT"
],
"leaflet_url": null,
"authorised_at": "2025/08/18",
"procedure_number": "EMEA/H/C/006438",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/25/1964",
"additional_monitoring": "Y"
}See everything about aflibercept.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.